CytoDyn restructures $43.8M Samsung debt; payment contingent on revenue

CytoDyn Inc.

Total balance of $43,821,231.32 restructured; only $250,000 due by Dec 31, 2024; remainder contingent on 20% of qualifying annual revenue.
Interest will not accrue on the balance during repayment period; debt is repayable only upon achieving defined 'Revenue' events.
Letter Agreement terminates Master Services Agreement from April 2019; Samsung will ship specified drug product to storage at CytoDyn’s discretion.
CytoDyn states it has sufficient drug product and substance for planned clinical activity; will transition manufacturing services to other current providers.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

CytoDyn Inc. terminated Letter Agreement with Samsung BioLogics Co., Ltd. valued at $43,821,231.32 total balance, $250,000 due by Dec 31, 2024, remainder contingent on Revenue event (effective 2024-04-03).

Action: termination
Counterparty: Samsung BioLogics Co., Ltd.
Value: $43,821,231.32 total balance, $250,000 due by Dec 31, 2024, remainder contingent on Revenue event
Effective: 2024-04-03

Exact text from the filing

On April 3, 2024, CytoDyn Inc. (the “Company”) and Samsung BioLogics Co., Ltd. (“Samsung”) executed an agreement (the “Letter Agreement”), wherein the parties reached agreement for an orderly process for winding down services and a restructuring of the amount payable by the Company to Samsung (the “Total Balance”).

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-004802

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.